The Fifth Circuit refused to revive claims by a woman alleging neurological harm from a generic form of heartburn medicine Reglan, saying the U.S. Supreme Court’s ruling in Pliva Inc. v. Mensing doesn’t make brand-name drugmakers liable for generic versions of their products.


To read this complete article visit Law360.
Downloads –